India's Kopran rises on getting no observations after USFDA inspection at API unit
** Shares of Kopran KPRN.NS up 5% to 200 rupees ** The integrated pharma co says USFDA concluded inspection at API unit in Mahad, Maharashtra with no observations ** More than 480,000 shares traded, 1.5x its 30-day moving avg ** KPRN trims YTD losses to ~6% (Reporting by Anuran Sadhu in Bengaluru) ((Anuran.Sadhu@thomsonreuters.com; +91 8697274436;))
Recent news on Kopran
See all newsBrief: Kopran Says EU Medicine Authority Conducts GMP Inspection At Khopran Khopoli Facility Sept 18-23, 2026
Brief: Kopran June-Quarter Consol Profit 67 Million Rupees
India's Kopran rises as quarterly profit nearly doubles
Brief: Kopran March-Quarter Consol Net Profit 188.7 Million Rupees
Brief: Kopran Flags Cyber-Attack At Its Khopoli Factory